Amyloid Gains Converts in Debate Over Alzheimer’s Treatments
Samuel Gandy, MD, PhD, discusses the success of a new Alzheimer's drug from Eisai Co., which has helped quiet a debate over a leading theory on what causes the disease and how to treat it.